Clinical trial • Phase I • Neurology
ALN-SNCA for Parkinson's disease
Phase I trial of ALN-SNCA for Parkinson's disease. 23 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Parkinson's disease
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 30-07-2025
- First CTIS Authorization Date
- 17-11-2025
Trial design
Phase I trial across 1 site in Netherlands.
- Target Sample Size
- 23
Eligibility
Recruits 23 Vulnerable populations not selected; adult participants only; no assent/consent handling details provided..
- Vulnerable Population
- Vulnerable populations not selected; adult participants only; no assent/consent handling details provided.
Recruitment
- Planned Sample Size
- 23
- Recruitment Window Months
- 42
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 23
Netherlands
- Earliest CTIS Part Ii Submission Date
- 05-11-2025
- Latest Decision Or Authorization Date
- 17-11-2025
- Processing Time Days
- 12
- Number Of Sites
- 1
- Number Of Participants
- 23
Sites
- Site Name
- Centre for Human Drug Research
- Department Name
- Center for Human Drug Research
- Contact Person Name
- Philip Kremer
- Contact Person Email
- PKremer@chdr.nl
- Number Of Participants
- 23
Sponsor
Primary sponsor
- Full Name
- Regeneron Pharmaceuticals Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- ALN-SNCA
- First In Human
- Yes
Related trials
Other published trials that may interest you.